Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
Elvira D'AndreaAaron S KesselheimJessica M FranklinEmily H JungSpencer Phillips HeyElisabetta PatornoPublished in: Cardiovascular diabetology (2020)
In this exploratory analysis, history of cardiovascular disease appeared to modify the treatment effect of SGLT2i or GLP1-RA on MACE. Chronic kidney disease and uncontrolled diabetes should be further investigated as potential effect modifiers.
Keyphrases
- cardiovascular disease
- type diabetes
- cardiovascular events
- chronic kidney disease
- coronary artery disease
- rheumatoid arthritis
- single cell
- insulin resistance
- cardiovascular risk factors
- replacement therapy
- systemic sclerosis
- human health
- atomic force microscopy
- idiopathic pulmonary fibrosis
- interstitial lung disease
- drug induced
- adverse drug
- data analysis